Productivity losses associated with premature mortality due to cancer in Russia: A population-wide study covering 2001–2030

Abstract

Aims: Productivity losses related to premature cancer mortality have been assessed for most developed countries but results for Russia are limited to cross-sectional reports. The aim of this study was to quantify productivity costs due to cancer mortality in Russia between 2001 and 2015 and project this to 2030. Methods: Cancer mortality data (2001–2015) were acquired from the State Cancer Registry, whereas population data, labour force participation rates and annual earnings were retrieved from the Federal State Statistics Service. Cancer mortality was projected to 2030 and the human capital approach was applied to estimate productivity losses. Results: The total annual losses increased from US6.5b in 2001–2005 to US$8.1b in 2011–2015, corresponding to 0.24% of the annual gross domestic product. The value is expected to remain high in 2030 (US$7.5b, 0.14% of gross domestic product). Productivity losses per cancer death are predicted to grow faster in women (from US$18,622 to US$22,386) than in men (from US$25,064 to US$28,459). Total losses were found to be highest for breast cancer in women (US$0.6b, 20% of overall losses in women) and lung cancer in men (US$1.2b, 24%). The absolute predicted change of annual losses between 2011–2015 and 2026–2030 was greatest for cervix uteri (+US$214m) in women and for lip, oral and pharyngeal cancers in men (+US$182m). Conclusions: In Russia, productivity losses due to premature cancer mortality are substantial. Given the expected importance especially for potentially preventable cancers, steps to implement effective evidence-based national cancer control policies are urgently required.

Cancer screening at the level of state programs: review, recommendations and management

“…Затраты на скрининг включают все затраты на организацию и проведение программы, затраты на дополнительное лечение случаев, которые не были бы диагностированы без скрининга, и экономию затрат на лечение за счет сокращения количества диагностированных на поздних стадиях случаев, последующее диагностическое наблюдение и лечение любых осложнений скрининга, а также затраты на случаи гипердиагностики. Также в эти затраты могут включаться такие факторы, как потеря рабочего времени из-за участия населения в скрининге и другие связанные с этим расходы [31].…”

Economic challenges of oncological diseases’ pharmacotherapy

“…6,5 млрд долл., а в 2011-2015 гг. увеличились до 8,1 млрд долл., что соответствует 0,24% ВВП [15]. Совокупные годовые затраты, обусловленные некоторыми видами рака в РФ, и их структура приведены в таблице 1.…”

The Anticancer Drug Discovery Potential of Marine Invertebrates from Russian Pacific

“…These numbers will be growing with the overall population rise, and especially with the growth in the proportions of aged people. The global economic loss due to cancer is above $1 trillion annually [76] ($8.1 billion annually in Russia [77]). Despite the enormous efforts and numerous achievements in the prevention and treatment of cancer, the overall improvements as measured e.g., by the global mortality are modest.…”